Regenicin, Inc. Share Price Other OTC
Equities
RGIN
US75887Q1022
Biotechnology & Medical Research
Sales 2021 | - | Sales 2022 | - | Capitalization | 5L 4.1Cr |
---|---|---|---|---|---|
Net income 2021 | - 0 | Net income 2022 | - 0 | EV / Sales 2021 | - |
Net Debt 2021 | 6L 4.99Cr | Net Debt 2022 | 6L 5.23Cr | EV / Sales 2022 | - |
P/E ratio 2021 |
-2
x | P/E ratio 2022 |
-0.71
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 79.1% |
Managers | Title | Age | Since |
---|---|---|---|
Randall McCoy
CEO | Chief Executive Officer | 74 | 15/10/15 |
John Weber
DFI | Director of Finance/CFO | 74 | 13/10/13 |
J. Nelson
CTO | Chief Tech/Sci/R&D Officer | 75 | 15/10/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Weber
DFI | Director of Finance/CFO | 74 | 13/10/13 |
Randall McCoy
CEO | Chief Executive Officer | 74 | 15/10/15 |
1st Jan change | Capi. | |
---|---|---|
+15.23% | 12TCr | |
+19.00% | 11TCr | |
+18.86% | 2.57TCr | |
-25.38% | 1.9TCr | |
-20.39% | 1.58TCr | |
-20.10% | 1.53TCr | |
-46.87% | 1.49TCr | |
+60.43% | 1.48TCr | |
+4.66% | 1.41TCr |